Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialYolanda Barbáchano, Wasat Mansoor, Tom Crosby et al.|The Lancet Oncology|2013Cited by 728
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety reportAlicia Okines, David Cunningham, Ruth E. Langley et al.|Annals of Oncology|2012Cited by 67
A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).Tom Samuel Waddell, David Cunningham, Ian Chau et al.|Journal of Clinical Oncology|2012Cited by 49
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trialsAlicia Okines, Andrew Wotherspoon, David González de Castro et al.|European Journal of Cancer|2013Cited by 40
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancerTim Meyer, Hiroki Kato, Martyn Caplin et al.|European Journal of Cancer|2009Cited by 39